Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 5
Submit an article Journal homepage
168
Views
14
CrossRef citations to date
0
Altmetric
Drug Evaluations

The use of endostatin in the treatment of solid tumors

Michalis V Karamouzis National & Kapodistrian University of Athens Medical School, Department of Biological Chemistry, Athens, Greece
&
Stergios J Moschos University of Pittsburgh Cancer Institute, Hillman Cancer Center Research Pavilion, Suite 1.32, 5117 Centre Avenue, Pittsburgh, 15213 PA, USA +1 001 412 623 2294; +1 001 412 623 7704; [email protected]
Pages 641-648 | Published online: 16 Apr 2009

Bibliography

  • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
  • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
  • Folkman J. Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res 2006;312:594-607
  • Tomono Y, Naito I, Ando K, et al. Epitope-defined monoclonal antibodies against multiplexin collagens demonstrate that type XV and XVIII collagens are expressed in specialized basement membranes. Cell Struct Funct 2002;27:9-20
  • Heljasvaara R, Nyberg P, Luostarinen J, et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 2005;307:292-304
  • Wen W, Moses MA, Wiederschain D, et al. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6
  • Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000;19:1187-94
  • Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002;21:1535-44
  • Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9:811-4
  • Ricard-Blum S, Feraud O, Lortat-Jacob H, et al. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J Biol Chem 2004;279:2927-36
  • Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-3
  • Clamp A, Blackhall FH, Henrioud A, et al. The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate. J Biol Chem 2006;281:14813-22
  • Skovseth DK, Veuger MJ, Sorensen DR, et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 2005;105:1044-51
  • Digtyar AV, Pozdnyakova NV, Feldman NB, et al. Endostatin: current concepts about its biological role and mechanisms of action. Biochemistry (Mosc) 2007;72:235-46
  • Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63
  • Mallery SR, Morse MA, Wilson RF, et al. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion. J Cell Biochem 2003;89:133-43
  • O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85
  • Xu F, Ma Q, Sha H. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst 2007;24:445-92
  • Marshall E. Cancer therapy. Setbacks for endostatin. Science 2002;295:2198-9
  • Yamaguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999;18:4414-23
  • Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-6
  • Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001;98:1024-9
  • Ma L, Elliott SN, Cirino G, et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 2001;98:6470-5
  • Aref S, El-Sherbiny M, Azmy E, et al. Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia. Hematology 2008;13:95-100
  • Kurschat P, Eming S, Nashan D, et al. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 2007;156:653-8
  • Suzuki M, Iizasa T, Ko E, et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002;35:29-34
  • No authors listed. From the editors desk. Matrix Biol 2002;21:309-10
  • Eder JP Jr, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-84
  • Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-803
  • Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-31
  • Sim BK, Fogler WE, Zhou ZH, et al. Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999;3:41-51
  • Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-74
  • Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a Phase I clinical trial with endostatin. Clin Cancer Res 2001;7:3366-74
  • Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20:3804-14
  • Hansma AH, Broxterman HJ, van der Horst I, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a Phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol 2005;16:1695-701
  • Lin X, Huang H, Li S, et al. A Phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007;6:648-53
  • Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-61
  • Moschos SJ, Odoux C, Land SR, et al. Endostatin plus interferon-α2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 2007;17:193-200
  • Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006;24:3164-71
  • Rosewicz S, Detjen K, Scholz A, et al. Interferon-α: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004;80(Suppl 1):85-93
  • Song HF, Liu XW, Zhang HN, et al. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin 2005;26:124-8
  • Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007;361:79-84
  • Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol 2006;24:117-8
  • Yang L, Wang JW, Sun Y, et al. Randomized Phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2006;28:138-41
  • Wang JW, Sun Y, Liu YY, et al. Results of randomized, multicenter, double-blind Phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer 2005;8:283-90
  • Huang C, Li K, Wei XY, et al. Circulating endothelial cells in the peripheral blood of advanced NSCLC patients. Zhonghua Zhong Liu Za Zhi 2006;28:780-3
  • Davis DW, Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004;10(1 Pt 1):33-42
  • Cobleigh MA, Langmuir VK, Sledge GW, et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.